GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Schott Pharma AG & CO KGaA (CHIX:1SXPd) » Definitions » Capex-to-Operating-Cash-Flow

Schott Pharma AG KGaA (CHIX:1SXPD) Capex-to-Operating-Cash-Flow : 0.87 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Schott Pharma AG KGaA Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Schott Pharma AG KGaA's Capital Expenditure for the three months ended in Dec. 2024 was €-21.13 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2024 was €24.37 Mil.

Hence, Schott Pharma AG KGaA's Capex-to-Operating-Cash-Flow for the three months ended in Dec. 2024 was 0.87.


Schott Pharma AG KGaA Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Schott Pharma AG KGaA's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Schott Pharma AG KGaA Capex-to-Operating-Cash-Flow Chart

Schott Pharma AG KGaA Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24
Capex-to-Operating-Cash-Flow
0.82 0.75 0.84 0.97 0.65

Schott Pharma AG KGaA Quarterly Data
Sep20 Sep21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 1.11 0.41 0.85 0.87

Competitive Comparison of Schott Pharma AG KGaA's Capex-to-Operating-Cash-Flow

For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Schott Pharma AG KGaA's Capex-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Schott Pharma AG KGaA's Capex-to-Operating-Cash-Flow falls into.


;
;

Schott Pharma AG KGaA Capex-to-Operating-Cash-Flow Calculation

Schott Pharma AG KGaA's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Sep. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-145.296) / 225.326
=0.64

Schott Pharma AG KGaA's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-21.127) / 24.374
=0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Schott Pharma AG KGaA  (CHIX:1SXPd) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Schott Pharma AG KGaA Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Schott Pharma AG KGaA's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Schott Pharma AG KGaA Business Description

Traded in Other Exchanges
Address
Hattenbergstrasse 10, Mainz, RP, DEU, 55122
Schott Pharma AG & CO KGaA caters to the pharma, biotech and life science industry by providing containment solutions and delivery systems for injectable drugs. Its segments include; Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of the revenue is generated from Drug Containment Solutions segment which includes products like vials, cartridges and ampoules for safe drug containment. Geographically, the company generates revenue from Europe, Middle East, Africa (EMEA), Asia and South Pacific, North America and South America.

Schott Pharma AG KGaA Headlines

No Headlines